Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
EVFM Evofem Biosciences	$0.01	$0.01	$0.01 ▼ $0.02	$1.19M	-0.99	413,165 shs	300,879 shs
GRTX Galera Therapeutics	$0.02 +0.5%	$0.03	$0.02 ▼ $0.08	$1.63M	1.91	88,898 shs	48,050 shs
ORPN Bioblast Pharma	$1.09 +0.9%	$19.65	$6.16 ▼ $30.00	$458K	1.41	N/A	438,608 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	+5.26%	+3.09%	0.00%	+13.64%	+3.09%
GRTX Galera Therapeutics	+0.47%	-4.44%	-16.99%	-8.51%	-65.60%
ORPN Bioblast Pharma	0.00%	+2.86%	-3.74%	+13.68%	-10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	1.8957 of 5 stars	0.0	5.0	0.0	4.8	3.1	0.0	0.0
GRTX Galera Therapeutics	0.1543 of 5 stars	0.0	3.0	0.0	0.0	0.0	1.7	0.0
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A
ORPN Bioblast Pharma	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	($2.41) per share	N/A
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	$7.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
EVFM Evofem Biosciences	$52.98M	-$0.07	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
GRTX Galera Therapeutics	-$59.08M	-$0.19	N/A	∞	N/A	N/A	N/A	-99.34%	N/A
ORPN Bioblast Pharma	-$5.94M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
EVFM Evofem Biosciences	N/A	0.11	0.09
GRTX Galera Therapeutics	N/A	9.74	9.74
ORPN Bioblast Pharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
EVFM Evofem Biosciences	0.22%
GRTX Galera Therapeutics	50.77%
ORPN Bioblast Pharma	4.47%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
EVFM Evofem Biosciences	0.01%
GRTX Galera Therapeutics	12.90%
ORPN Bioblast Pharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
GRTX Galera Therapeutics	30	75.46 million	47.38 million	Optionable
ORPN Bioblast Pharma	N/A	420,000	N/A	Not Optionable

ORPN, GRTX, ASLN, and EVFM Headlines

Recent News About These Companies

FIRST TRADE: Indian equities open weak; Sensex down 203 pts, Nifty falls 0.41% to 24,204

November 6, 2024 | zeebiz.comZ

Positive Outlook on BridgeBio Pharma’s BBP-812 Gene Therapy: Buy Rating Reaffirmed

October 25, 2024 | markets.businessinsider.com

Promising Outlook and Strategic Growth Support Buy Rating for Catalyst Pharma

October 19, 2024 | markets.businessinsider.com

Positive Developments and Potential Upside for BridgeBio Pharma: An Overweight Rating on Acoramidis Approval Prospects and Pipeline Catalysts

October 18, 2024 | markets.businessinsider.com

'Biopharma Crescent' sees rapid expansion fueled by recent investments

October 12, 2024 | msn.com

Buy Rating Affirmed on Urogen Pharma’s Promising Pipeline and Market Expansion Potential

October 4, 2024 | markets.businessinsider.com

Pharmaceutical giant partners with biotech company to produce animal-free protein for global nutrition: 'A win-win combination'

September 27, 2024 | msn.com

A weight loss drug developer's stock soars after a $198 million IPO

September 26, 2024 | msn.com

BioAge prices $198M IPO, validating pivot to obesity drug research

September 26, 2024 | biopharmadive.comB

A weight loss drug maker is aiming for a big IPO

September 25, 2024 | msn.com

Roche Narrows Pharma Pipeline Amid Push Into Obesity Market

September 24, 2024 | msn.com

Spin-out biotechs: bridging the gap between academia and pharma

September 22, 2024 | pharmaphorum.comP

BioMarin Pharmaceutical: A Volatile But Growing Trajectory

September 17, 2024 | seekingalpha.com

BridgeBio Pharma Stops Development Of BBP-631 For Congenital Adrenal Hyperplasia

September 11, 2024 | nasdaq.com

BioMarin Pharmaceutical: Hold Rating Amidst Growth Potential and Competitive Challenges

September 9, 2024 | markets.businessinsider.com

BioMarin Pharmaceutical: A Buy Rating Based on Strong Growth and Operational Efficiency Strategy

September 6, 2024 | markets.businessinsider.com

BioMarin Announces New Strategy, Structure Aimed at Reaching $4B Revenue Goal

September 6, 2024 | precisionmedicineonline.comP

Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance

September 4, 2024 | statnews.comS

Blast at Indian pharma factory kills 15 and injures 40, official says

August 23, 2024 | msn.com

BridgeBio Pharma: Positioned for Growth with Acoramidis’ Market Potential and Positive Outlook amidst Stabilized Expectations

August 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

ORPN, GRTX, ASLN, and EVFM Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/27/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)

As of 03:53 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Galera Therapeutics NASDAQ:GRTX

$0.02 +0.00 (+0.47%)

As of 02:20 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Bioblast Pharma NASDAQ:ORPN

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time